Clascoterone, an acne treatment that blocks DHT, is being developed for scalp use against hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.
The conversation is about improving scalp appearance by regaining adipose tissue and making the skin look better using scalp massages and a moisturizer with hyaluronic acid, ceramides, and urea. The user is not trying to regrow hair but wants to improve the scalp's thickness and appearance.
Piroctone olamine and ketoconazole are both effective for reducing dandruff and hair shedding, with potential benefits for hair thickness and scalp health. Piroctone olamine may be as effective or better than ketoconazole in certain conditions, yet it is often overlooked.
The conversation discusses alternatives to 5AR inhibitors for hair loss treatment, suggesting options like minoxidil, KX-826, pyrilutimide, microneedling, and topical bicalutamide. Concerns about side effects and the effectiveness of these treatments are also highlighted.
Hair cell therapy and follicle cloning are still in experimental stages, with treatments like hair multiplication and regenerative hair therapy being marketed but not yet proven to create unlimited new follicles. There is skepticism about the effectiveness and legitimacy of these treatments, with some considering them scams.
The user is seeking advice for the best topical treatment to combat their ongoing hair loss, despite already using oral dutasteride, RU-58841, and minoxidil. They are considering adding CB-03-01 or topical Spiro to their regimen to lower testosterone levels at the follicles.
PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.
The conversation discusses whether a longtime NW7 scalp has vellus hairs under a microscope or is completely smooth. Treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation discusses the scalp tension theory as a potential factor in hair loss, alongside DHT, inflammation, and other mechanisms. Treatments mentioned include finasteride, minoxidil, and botox injections, with some users exploring additional methods due to varying effectiveness.
The user is experiencing rapid hair loss, progressing from Norwood 3 to 7, with thinning at the crown and receding hairline. Suggested treatments include finasteride, minoxidil, ketoconazole shampoo, and CBD with MCT oil.
A user with diffuse thinning noticed stubble-like hairs on their scalp after using 2% ketoconazole shampoo, dermarolling, castor oil, Vitamin D3, biotin, and iron supplements. They are unsure if this indicates regrowth or miniaturized hairs.
The user visited a trichologist due to ineffective topical finasteride treatment for hair loss. The trichologist recommended a new regimen including a two-month course of locoidon (cortisone 0.1%), followed by a solution containing minoxidil, hydrocortisone butirrate, estrone, progesterone, tocopherol acetate, trichosol, and transcutol.
The conversation discusses the effectiveness of finasteride and microneedling for treating hair loss. The linked article is seen as an advertisement for these treatments.
The conversation humorously discusses hair loss treatments, mentioning spironolactone and cyproterone acetate. It reflects a sense of frustration and satire about the effectiveness of these treatments.
Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.
People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.
Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.
Pyrilutamide (KX-826) is discussed as an anti-androgen treatment for hair loss, with mixed user experiences. Some users report no results, while others find it mildly effective.
Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.
The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.
The conversation discusses skepticism about the effectiveness of scalp tension theory and scalp massagers for hair regrowth, contrasting it with treatments like finasteride and minoxidil, which have more user-reported results. Participants question the belief in scalp tension theory, suggesting it may be a marketing tactic, while others argue for a multifactorial approach to hair loss.
Ell-Cranell and Eucapil are discussed as hair loss treatments, with Ell-Cranell being a weak estrogen and DHT inhibitor that may reduce hair loss without systemic side effects. Alfatradiol is the active ingredient in these products.
The conversation discusses hair transplants, including the use of techniques like FUE and the importance of a good donor area to avoid visible bald patches. It also touches on alternative treatments like Minoxidil, Finasteride, and Pyrolutimide, and debates the idea of embracing baldness versus seeking treatments.
John Cazale's hairline showed strong recession at the temples but maintained solid volume and density, sparking discussion on different hair loss patterns and the importance of overall hair density. Treatments like Minoxidil and Spironolactone were mentioned as potential factors in maintaining hair, though genetics and styling were also considered significant.
Breezula (clascoterone) and Formula 82F (topical finasteride) are treatments for hair loss that block DHT differently; Breezula competes with DHT at the hormone receptor site without systemic effects, while 82F inhibits the enzyme that converts testosterone to DHT. Breezula may work for those who don't respond to finasteride and vice versa.
The post discusses the user's experience with hair loss treatment using finasteride, clobetasol propionate, and ketoconazole shampoo. The conversation warns about the potential side effects of clobetasol, a powerful topical steroid, and emphasizes its short-term usage.
A user underwent a second hair transplant for increased density and to address hair loss in the crown area, with 3,800 grafts at a cost of 2,200 euros at Estepalace, including additional services. Some commenters discussed the appearance of the hairline and the importance of using DHT blockers like finasteride or dutasteride post-transplant.
The user is experiencing hair thinning on the sides and back of the head while the top remains thick. A reply suggests it might be retrograde alopecia.
Kintor is producing a cosmetic with KX826, starting at 0.5% concentration and moving to 1%. The 0.5% concentration wasn't as effective as minoxidil and finasteride, but the 1% concentration shows promise.